Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects

被引：0
|
作者：
Roedder, Silke [1 ]
Wendt, Emily [2 ]
Burris, Chad [2 ]
Nazareon, Jonathan [2 ]
Park, Grace [3 ]
Pangilinan, Phil [2 ]
Huang, Gianna [2 ]
Mathur, Anubhav [2 ]
Taylor, James [2 ]
Billin, Andrew [2 ]
Matzkies, Franziska [4 ]
机构：
[1] Gilead Sci, Menlo Pk, CA USA
[2] Gilead Sci, Foster City, CA USA
[3] Gilead Sci, Seattle, WA USA
[4] Gilead Sci Inc, Foster City, CA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0185
引用
收藏
页码：371 / 372
页数：2
相关论文
共 50 条
  • [31] A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects
    Faison, Shamia L.
    Batonga, Joelle
    Arumugham, Thangam
    Bartkus, Angela
    Morrison, Marion
    Mullin, Mark J.
    Tippin, Tim
    Naderer, Odin
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2025,
  • [32] BCX9930, an Oral Factor D Inhibitor, for the Potential Treatment of Alternative Pathway Mediated Diseases: Interim Results of a Phase 1 Study in Healthy Subjects
    Davidson, Matthew
    Mathis, Amanda
    Mair, Stuart
    Gesty-Palmer, Diane
    Cornpropst, Melanie
    Sheridan, William P.
    Chen, Xilin
    Reynolds, David
    Parker, Cynthia
    Babu, Yarlagadda S.
    BLOOD, 2020, 136
  • [33] A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Hmpl-523 in Australian Male Healthy Subjects
    Lickliter, Jason
    Wu, Yan
    Hua, Ye
    Yuan, Irena
    Dai, Guangxiu
    Li, Xiong
    Wang, Jian
    Sai, Yang
    Sun, Zhongcui
    Pan, Angela
    Li, Jing
    Su, Weiguo
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [34] A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
    Noboru Yamamoto
    Baek-Yeol Ryoo
    Bhumsuk Keam
    Masatoshi Kudo
    Chia-Chi Lin
    Futoshi Kunieda
    Howard A. Ball
    Diarmuid Moran
    Kanji Komatsu
    Kentaro Takeda
    Musashi Fukuda
    Junji Furuse
    Satoshi Morita
    Toshihiko Doi
    Investigational New Drugs, 2020, 38 : 445 - 456
  • [35] A PHASE 1, SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AG-519, AN ALLOSTERIC ACTIVATOR OF PYRUVATE KINASE-R IN HEALTHY SUBJECTS
    Barbier, A.
    Cutie, J.
    Connor, G.
    Merica, E.
    Kung, C.
    Le, K.
    Yang, H.
    Kosinski, P. A.
    Silverman, L.
    Yuan, Z. J.
    Agresta, S.
    Cohen, M.
    HAEMATOLOGICA, 2016, 101 : 301 - 301
  • [36] A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
    Vickers, Richard
    Robinson, Neil
    Best, Emma
    Echols, Roger
    Tillotson, Glenn
    Wilcox, Mark
    BMC INFECTIOUS DISEASES, 2015, 15
  • [37] A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
    Richard Vickers
    Neil Robinson
    Emma Best
    Roger Echols
    Glenn Tillotson
    Mark Wilcox
    BMC Infectious Diseases, 15
  • [38] Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study
    Helen Jenkins
    Richard Jenkins
    Alain Patat
    Clinical Drug Investigation, 2017, 37 : 311 - 316
  • [39] Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study
    Jenkins, Helen
    Jenkins, Richard
    Patat, Alain
    CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 311 - 316
  • [40] A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies
    Yamamoto, Noboru
    Ryoo, Baek-Yeol
    Keam, Bhumsuk
    Kudo, Masatoshi
    Lin, Chia-Chi
    Kunieda, Futoshi
    Ball, Howard A.
    Moran, Diarmuid
    Komatsu, Kanji
    Takeda, Kentaro
    Fukuda, Musashi
    Furuse, Junji
    Morita, Satoshi
    Doi, Toshihiko
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 445 - 456
12345